Patent expiry and costs for anti-cancer medicines for clinical use

Brian Godman*, Claudia Wild, Alan Haycox

*Corresponding author for this work

Research output: Contribution to journalComment/debate

20 Citations (Scopus)

Abstract

Venkatesan S et al. have researched patent rights and pricing for (non-)tyrosine kinase inhibitors. It is not clear why the patent rights are so long and why prices of (non-)tyrosine kinase inhibitors can be high. These issues are discussed.

Original languageEnglish
Pages (from-to)105-106
Number of pages2
JournalGaBI Journal
Volume6
Issue number3
DOIs
Publication statusPublished - 2017
Externally publishedYes

Keywords

  • Cancer medicines
  • Generics
  • Health gain
  • Prices
  • Tyrosine kinase inhibitors (TKI)

Fingerprint

Dive into the research topics of 'Patent expiry and costs for anti-cancer medicines for clinical use'. Together they form a unique fingerprint.

Cite this